Meetings this week on future of OPH division

Suns investment in dry eye was spot on. This will make tons of cash since Restasis was the only player. Anyone who thinks OPT is going away, you are clueless. Everyone knows Bromsite with a 15% market share wouldn’t get it done, but you start with one product. Now you got two in your bag with dry eye and you expand your base that much more. Even with 2-4 new generic dry eye drugs out there, this will be huge.

 

You’re crazy.

 

"Kool-Aid" !!

If it's so good, why won't anyone take the BU Head job ?

 

You are making a MAJOR assumption--that OTX will be approved the first time.
Restasis failed on first submission, Xiidra failed first submission, low dose bromfenac (Remura) failed, INSPIRE had a dry-eye candidate which also failed.
If OTX fails do you honestly think Sun Oph will be allowed to stay?-----sorry that answer will be "no"---just chalk this company up to a FAIL as well.

 

This is true. If OTX fails ophtha is DOA. But in all likelihood it will be approved. FDA accepted the file so looks to be okay

 

Part 1 of the equation is dependent on FDA approval.
However, part 2 is dependent on Sun's ability to execute.
And that's where the wheels fall off the wagon.

They'll be on their 3rd VP leader in 6 months IF and when they can convince someone to join the company. Let's see - you're supposed to be launching a major new drug and two VP / BU Heads quit along the way and you can't find a backfill.

#wordisoutaboutsun

 

So delusional and brainwashed. 15% marketshare with Bromshit? Oh, I forgot we don’t count generics in the calculations. If we did it would’ve more like 1% marketshare. How does 200 RXs per week per district support a field force, marketing team, access team, and over paid executives? Do the math morons. India is, and they are not happy. One more question for you Sum Oph folks...why so many leaders leaving? Only one willing to stay is that blowhard BJ. All he’s good for is giving BJ’s to Doctors for a few scripts.

 

My manager thinks so and I believe him.

 

This is hysterical.

 

Dumbass- All those companies and drugs you mentioned did all the dirty work. Cyclosporine lookalikes are virtually cook book formulations. Phase 3 data is a formality since FDA knows they work, all they are worried about is adverse side affects which by now is trivial. OTX will pass on first review and predicted to be ready by fall. AND with its profile being preservative free and better efficacy than Restasis, this will make oodles for Sun! BTW- I dont work for Sun!